Studio piattaforma di fase 1b/2 su combinazioni immunoterapeutiche selezionate in partecipanti con carcinoma polmonare non a piccole cellule (NSCLC) avanzato
Uno studio di fase 1b/2, multicentrico, su piattaforma in aperto su combinazioni immunoterapeutiche selezionate in partecipanti adulti con carcinoma polmonare non a piccole cellule (NSCLC) avanzato precedentemente non trattato con elevata espressione di PD-L1
This is a Phase 1b/2 study evaluating the anti-PD1 antibody, cemiplimab, in combination with either S095018 (anti-TIM3 antibody), S095024 (anti-CD73 antibody), or S095029 (anti-NKG2A antibody) in adult participants with previously untreated advanced/metastatic non-small cell lung cancer (NSCLC) with high PD-L1 expression. The study includes two parts: part A, the combination-therapy safety lead-in phase to determine the recommended dose for expansion (RDE) for S095018, S095024, and S095029 in combination with cemiplimab and part B, the randomized dose expansion phase to assess the efficacy of S095018, S095024, or S095029 in combination with cemiplimab. Study treatment will be administered for a maximum of 108 weeks, or until confirmed disease progression per iRECIST and/ or until meeting other treatment discontinuation criteria.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Fase 2
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
-
Albury, Australia, 2640
- Border Medical Oncology Research Unit
-
Bedford Park, Australia, 5042
- Flinders Medical Centre
-
St Albans, Australia, 3021
- Sunshine Hospital
-
Traralgon, Australia, 3844
- Latrobe Regional Health
-
-
-
-
-
Sankt Pölten, Austria, 3100
- Universitatsklinikum St. Poelten
-
Vienna, Austria, 1090
- Medical University of Vienna - Akh
-
-
-
-
-
Hasselt, Belgio, 3500
- Jessa Ziekenhuis
-
-
-
-
-
Barretos, Brasile, 14784-400
- Hospital de Amor - Barretos
-
Chapecó, Brasile, 89812618
- Supera Oncologia
-
Curitiba, Brasile, 80810-050
- CIONC
-
Natal, Brasile, 59035-055
- Liga Contra O Cancer - Natal
-
Porto Alegre, Brasile, 90020-090
- Santa Casa de Porto Alegre
-
Porto Alegre, Brasile, 90619-900
- Hospital São Lucas Da Pucrs
-
Rio de Janeiro, Brasile, 22250-905
- Oncoclinicas Rj
-
São Paulo, Brasile, 01509-010
- Hospital A C Camargo
-
São Paulo, Brasile, 03102-002
- Hospital São Camilo
-
São Paulo, Brasile, 04538-132
- Oncoclinicas Sp
-
São Paulo, Brasile, 05652-900
- Hospital Albert Einstein
-
-
-
-
-
Dijon, Francia, 21079
- Centre Georges Francois Leclerc
-
Grenoble, Francia, 38043
- Chu Grenoble Alpes
-
Marseille, Francia, 13009
- Institut Paoli Calmette
-
Saint-Herblain, Francia, 44805
- Centre René Gauducheau/Inst de Cancér. de L'Ouest
-
Villejuif, Francia, 94805
- Institut Gustave Roussy
-
-
-
-
-
Hong Kong, Hong Kong
- Queen Mary Hospital
-
-
-
-
-
Aviano, Italia, 33081
- Centro Di Riferimento Oncologico
-
Meldola, Italia, 47014
- Inst. Romagnolo Per Lo Studio E La Cura Dei Tumori
-
Milan, Italia, 20162
- ASST Grande Ospedale Metropolitano Niguarda
-
Milan, Italia, 20133
- Irccs Fondazione Istituto Nazionale Dei Tumori
-
Milan, Italia, 20141
- Istituto Europeo Di Oncologia
-
Naples, Italia, 80131
- Ist. Nazionale Tumori Irccs Fondazione G Pascale
-
Perugia, Italia, 06132
- Azienda Ospedaliera S. Maria Della Misericordia
-
Roma, Italia, 00144
- Istituto Nazionale Tumori Regina Elena
-
Rozzano, Italia, 20089
- Istituto Clinico Humanitas I.R.C.C.S
-
-
-
-
-
London, Regno Unito, SW3 6JJ
- The Royal Marsden in Chelsea
-
London, Regno Unito, SM2 5PT
- The Royal Marsden in Sutton
-
Manchester, Regno Unito, M20 4BX
- The Christie Nhs Foundation Foundation Trust
-
-
-
-
-
Cluj-Napoca, Romania
- Inst Oncologic "Prof Dr I Chiricuta" Cluj Napoca
-
-
-
-
-
Barcelona, Spagna, 08035
- Vall D' Hebron Institute of Oncology (Vhio), University Hospital
-
Madrid, Spagna, 28007
- Hospital General Universitario Gregorio Marañón
-
Madrid, Spagna, 28027
- Clinica Universitaria de Navarra (Madrid)
-
Madrid, Spagna, 28050
- Hospital Univ. Hm Sanchinarro Start Ciocc Early Phase
-
Málaga, Spagna, 29010
- Hospital Universitario Virgen de La Victoria
-
Valencia, Spagna, 46026
- Hospital Universitario Y Politecnico La Fe
-
-
-
-
Michigan
-
Detroit, Michigan, Stati Uniti, 48202
- Henry Ford Health
-
-
Ohio
-
Canton, Ohio, Stati Uniti, 44718
- Gabrail Cancer Center
-
Columbus, Ohio, Stati Uniti, 43210
- Ohio State University Comprehensive Cancer Center
-
-
-
-
-
Taipei, Taiwan, 100225
- National Taiwan University Hospital
-
Taipei, Taiwan, 114202
- Tri-Service General Hospital
-
-
-
-
-
Farkasgyepű, Ungheria, 8582
- Farkasgyepu Tudogyogyintezet
-
Gyöngyös, Ungheria, 3200
- Bugat Pal Hospital
-
Pécs, Ungheria, 7624
- Pecsi Tudomanyegyetem, Klinikai Kozpont
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Adult patient aged ≥ 18 years
- Written informed consent
- Histologically (squamous or non-squamous) or cytologically documented locally advanced NSCLC not eligible for surgical resection and/or definitive chemoradiation, or metastatic NSCLC
- No prior systemic treatment for locally advanced or metastatic NSCLC
- High tumor cell PD-L1 expression [Tumor Proportion Score (TPS) ≥50%] based on documented status as determined by an approved test
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- Measurable disease as determined by RECIST v1.1
Exclusion Criteria:
- Tumors harboring driver mutations/genetic aberrations for which targeted therapies are approved as frontline treatment (e.g. EGFR mutation, ALK fusion oncogene, ROS1 aberrations)
- Prior immune checkpoint inhibitor therapy
- Active brain metastases
- Participants with active and uncontrolled hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
- Uncontrolled HIV infection. Participants with HIV who have controlled infection (undetectable viral load and CD4 count above 350 either spontaneously or on a stable antiviral regimen) are allowed to enroll
- Active, known or suspected autoimmune disease or immune deficiency
- History of hypersensitivity reactions to any ingredient of the investigational medicinal product (IMP) and other monoclonal antibody (mAbs) and/or their excipients
- History of interstitial lung disease, idiopathic pulmonary fibrosis, drug-induced pneumonitis, idiopathic pneumonitis or active pneumonitis ≥ grade 2
- History of inflammatory bowel disease or colitis ≥ grade 2
- History of hemophagocytic lymphohistiocytosis.
- Systemic chronic steroid therapy (>10mg/d prednisone or equivalent)
- Clinically significant infection, as assessed by the investigator
- Pregnant or breast-feeding (lactating) women
- Participants with a history of allogeneic organ transplantation (e.g., stem cell or solid organ transplant)
- Any medical condition that would in the investigator's judgement prevent the participant's participation in the clinical study
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: S095018 (anti-TIM3 antibody) in combination with cemiplimab
Part A: Combination-therapy safety lead-in |
Via IV infusion on Day 1 of each 21-day cycle 350 mg via IV infusion on Day 1 of each 21-day cycle |
|
Sperimentale: S095024 (anti-CD73 antibody) in combination with cemiplimab
Part A: Combination-therapy safety lead-in |
350 mg via IV infusion on Day 1 of each 21-day cycle Via IV infusion on Day 1 of each 21-day cycle |
|
Sperimentale: S095029 (anti-NKG2A antibody) in combination with cemiplimab
Part A: Combination-therapy safety lead-in |
350 mg via IV infusion on Day 1 of each 21-day cycle Via IV infusion on Day 1 of each 21-day cycle |
|
Sperimentale: S095018 (anti-TIM3 antibody) RDE in combination with cemiplimab
Part B: Randomized dose expansion |
350 mg via IV infusion on Day 1 of each 21-day cycle Via IV infusion on Day 1 of each 21-day cycle |
|
Sperimentale: S095024 (anti-CD73 antibody) RDE in combination with cemiplimab
Part B: Randomized dose expansion |
350 mg via IV infusion on Day 1 of each 21-day cycle Via IV infusion on Day 1 of each 21-day cycle |
|
Sperimentale: S095029 (anti-NKG2A antibody) RDE in combination with cemiplimab
Part B: Randomized dose expansion |
350 mg via IV infusion on Day 1 of each 21-day cycle Via IV infusion on Day 1 of each 21-day cycle |
|
Comparatore attivo: Cemiplimab (control arm)
Part B: Randomized dose expansion |
350 mg via IV infusion on Day 1 of each 21-day cycle |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Incidence and severity of dose-limiting toxicities (DLTs) during the first 2 cycles of combination treatment
Lasso di tempo: Through the end of the Cycle 2 (each cycle is 21 days)
|
Part A |
Through the end of the Cycle 2 (each cycle is 21 days)
|
|
Incidence and severity of adverse events (AEs)
Lasso di tempo: From the signed informed consent form (ICF) to 30 days after the last dose
|
Part A |
From the signed informed consent form (ICF) to 30 days after the last dose
|
|
Incidence and severity of serious adverse events (SAEs)
Lasso di tempo: From the signed ICF to 120 days after the last dose
|
Part A |
From the signed ICF to 120 days after the last dose
|
|
Adverse Events (AEs) Leading to Dose Interruption, Modification, or Delays
Lasso di tempo: From signed ICF through treatment discontinuation (up to 108 weeks of treatment)
|
Part A |
From signed ICF through treatment discontinuation (up to 108 weeks of treatment)
|
|
Adverse Events (AEs) Leading to Permanent Treatment Discontinuation
Lasso di tempo: From signed ICF through treatment discontinuation (up to 108 weeks of treatment)
|
Part A |
From signed ICF through treatment discontinuation (up to 108 weeks of treatment)
|
|
Objective Response (OR)
Lasso di tempo: Until study termination (approximately 2 years)
|
Part B: Participants who achieve complete response (CR) or partial response (PR), as per investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. |
Until study termination (approximately 2 years)
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Objective Response (OR)
Lasso di tempo: Until study termination (approximately 3 years)
|
Part A: Participants who achieve CR or PR, as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and immune RECIST (iRECIST) as assessed by the investigator. |
Until study termination (approximately 3 years)
|
|
Best Overall Response (BOR)
Lasso di tempo: Until study termination (approximately 3 years)
|
Part A and B: The best response designation using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and immune RECIST (iRECIST), recorded between the date of the first dose of treatment and the date of the first objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first. CR or PR used in the BOR requires a confirmation that is at least 4 weeks apart. |
Until study termination (approximately 3 years)
|
|
Duration of Response (DoR)
Lasso di tempo: Until study termination (approximately 3 years)
|
Part A and B: The time from the first documentation of CR or PR until the documented progressive disease (PD) or death, as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and immune RECIST (iRECIST) as assessed by the investigator. |
Until study termination (approximately 3 years)
|
|
Disease Control (DC)
Lasso di tempo: Until study termination (approximately 3 years)
|
Part A and B: Participants who achieved stable disease (SD), PR, or CR (based on participant's best response), as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and immune RECIST (iRECIST) as assessed by the investigator. |
Until study termination (approximately 3 years)
|
|
6-month Durable Response (6-month DR)
Lasso di tempo: Until study termination (approximately 3 years)
|
Part A and B: Continuous CR or PR for ≥ 6 months, recorded between the date of the first dose of treatment and the date of the first objectively documented progression per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or the date of subsequent anti-cancer therapy, whichever occurs first. |
Until study termination (approximately 3 years)
|
|
Progression-Free Survival (PFS)
Lasso di tempo: Until study termination (approximately 3 years)
|
Part A and B: The time from the first dose to the first documented PD or death due to any cause, whichever occurs first, as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and immune RECIST (iRECIST) as assessed by the investigator. |
Until study termination (approximately 3 years)
|
|
Plasma or serum concentration of S095018
Lasso di tempo: From first dose to 30 days after the last dose
|
Part A and B |
From first dose to 30 days after the last dose
|
|
Plasma or serum concentration of S095024
Lasso di tempo: From first dose to 30 days after the last dose
|
Part A and B |
From first dose to 30 days after the last dose
|
|
Plasma or serum concentration of S095029
Lasso di tempo: From first dose to 30 days after the last dose
|
Part A and B |
From first dose to 30 days after the last dose
|
|
Incidence and titer of anti-drug antibodies (ADA) directed against S095018
Lasso di tempo: From screening to 90 days after the last dose
|
Part A and B |
From screening to 90 days after the last dose
|
|
Incidence and titer of anti-drug antibodies (ADA) directed against S095024
Lasso di tempo: From screening to 90 days after the last dose
|
Part A and B |
From screening to 90 days after the last dose
|
|
Incidence and titer of anti-drug antibodies (ADA) directed against S095029
Lasso di tempo: From screening to 90 days after the last dose
|
Part A and B |
From screening to 90 days after the last dose
|
|
Incidence and severity of adverse events (AEs)
Lasso di tempo: From signed ICF to 30 days after the last dose
|
Part B |
From signed ICF to 30 days after the last dose
|
|
Incidence and severity of serious adverse events (SAEs)
Lasso di tempo: From signed ICF to 120 days after the last dose
|
Part B |
From signed ICF to 120 days after the last dose
|
|
Adverse Events (AEs) Leading to Dose Interruption, Modification, or Delays
Lasso di tempo: From signed ICF through treatment discontinuation (up to 108 weeks of treatment)
|
Part B |
From signed ICF through treatment discontinuation (up to 108 weeks of treatment)
|
|
Adverse Events (AEs) Leading to Permanent Treatment Discontinuation
Lasso di tempo: From signed ICF through treatment discontinuation (up to 108 weeks of treatment)
|
Part B |
From signed ICF through treatment discontinuation (up to 108 weeks of treatment)
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- SPLFIO-174
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data.
Access can be requested for all interventional clinical studies:
- used for Marketing Authorization (MA) of medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).
- where Servier is the Marketing Authorization Holder (MAH). The date of the first MA of the new medicine (or the new indication) in one of the EEA Member States will be considered for this scope.
In addition, access can be requested for all interventional clinical studies in patients:
- sponsored by Servier
- with a first patient enrolled as of 1 January 2004 onwards
- for New Chemical Entity or New Biological Entity (new pharmaceutical form excluded) for which development has been terminated before any Marketing authorization (MA) approval.
Periodo di condivisione IPD
After Marketing Authorization in EEA or US if the study is used for the approval.
Criteri di accesso alla condivisione IPD
Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- LINFA
- ICF
- RSI
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .